Results 261 to 270 of about 157,671 (305)

AZD-2563 AstraZeneca.

Current opinion in investigational drugs (London, England : 2000), 2003
AstraZeneca is developing AZD-2563, an oxazolidinone with a novel mechanism of action, for the potential treatment of gram-positive bacterial infections, including those caused by multidrug-resistant strains [349551], [399542]. As of December 2001, AZD-2563 had completed an escalating-dose phase I trial in the UK and was being developed in the US ...
openaire   +1 more source

New Deal For AstraZeneca

Chemical & Engineering News Archive, 2013
In a bid to stay competitive in treating respiratory diseases, AstraZeneca is paying up to $1.15 billion for the privately held biotech firm Pearl Therapeutics. The acquisition is the latest in the British drug company’s piecemeal rebuilding of a new-product pipeline that has fallen apart in recent years.
openaire   +1 more source

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study

Frontiers in Public Health, 2022
Elias Ali Yesuf, Abanoub Riad, Ahmad Sofi-Mahmudi   +2 more
exaly  

AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?

Journal of Neuroimmunology, 2021
Aaron De Souza
exaly  

Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?

Clinical Neurology and Neurosurgery, 2021
Alessandro Introna, Francesca Caputo, Carlo Santoro   +2 more
exaly  

Cerebral venous sinus thrombosis following intracerebral hemorrhage after COVID ‐19 AstraZeneca vaccination: A case report

Clinical Case Reports (discontinued), 2022
Arsh Haj Mohamad Ebrahim Ketabforoush, Matineh Nirouei, Nahid Abbasi Khoshsirat   +2 more
exaly  

A case of pityriasis rubra pilaris following AstraZeneca COVID-19 vaccine

JAAD Case Reports, 2022
Ian Simpson, Adrian Mar
exaly  

Side Effects Following Administration of the First Dose of Oxford-AstraZeneca’s Covishield Vaccine in Bangladesh: A Cross-Sectional Study

Infectious Disease Reports, 2021
Nishat Jahan, Fahad Imtiaz Rahman, Poushali Saha   +2 more
exaly  

‘‘AstraZeneca’’

IIC - International Review of Intellectual Property and Competition Law, 2014
openaire   +1 more source

A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca

Vaccines, 2022
Marian S Boshra, Raghda R S Hussein, Marwa Mohsen   +2 more
exaly